IN191236B - - Google Patents
Info
- Publication number
- IN191236B IN191236B IN775DE1999A IN191236B IN 191236 B IN191236 B IN 191236B IN 775DE1999 A IN775DE1999 A IN 775DE1999A IN 191236 B IN191236 B IN 191236B
- Authority
- IN
- India
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN775DE1999 IN191236B (pl) | 1999-05-25 | 1999-05-25 | |
AT00900300T ATE362759T1 (de) | 1999-05-25 | 2000-01-06 | Verfahren zur herstellung von amorphem atorvastatin kalzium |
BR0010923-1A BR0010923A (pt) | 1999-05-25 | 2000-01-06 | Processo para a produção de atorvastatina de cálcio amorfa |
CNA2005100525833A CN1680315A (zh) | 1999-05-25 | 2000-01-06 | 无定形阿托伐斯汀钙的制备方法 |
EP00900300A EP1185264B1 (en) | 1999-05-25 | 2000-01-06 | Process for the production of amorphous atorvastatin calcium |
DE60034946T DE60034946T2 (de) | 1999-05-25 | 2000-01-06 | Verfahren zur herstellung von amorphem atorvastatin kalzium |
CNB008080275A CN1196679C (zh) | 1999-05-25 | 2000-01-06 | 无定形阿托伐斯汀钙的制备方法 |
ES00900300T ES2284472T3 (es) | 1999-05-25 | 2000-01-06 | Procedimiento para la produccion de atorvastatina clacica amorfa. |
PCT/IB2000/000014 WO2000071116A1 (en) | 1999-05-25 | 2000-01-06 | Process for the production of amorphous atorvastatin calcium |
US09/979,475 US6528660B1 (en) | 1999-05-25 | 2000-01-06 | Process for the production of amorphous atorvastatin calcium |
PT00900300T PT1185264E (pt) | 1999-05-25 | 2000-01-06 | Processo para a produção de atorvastatina de cálcio amorfa |
DK00900300T DK1185264T3 (da) | 1999-05-25 | 2000-01-06 | Fremgangsmåde til fremstilling af amorft atorvastatin-calcium |
AU19967/00A AU778962B2 (en) | 1999-05-25 | 2000-01-06 | Process for the production of amorphous atorvastatin calcium |
MYPI20002283A MY133511A (en) | 1999-05-25 | 2000-05-24 | Process for the production of amorphous atorvastatin calcium |
ZA200109656A ZA200109656B (en) | 1999-05-25 | 2001-11-23 | Process for the production of amorphous atorvastatin calcium. |
HK02106699.9A HK1045118A1 (zh) | 1999-05-25 | 2002-09-12 | 無定形的阿伐他汀鈣的製備方法 |
US10/378,574 US20030149279A1 (en) | 1999-05-25 | 2003-03-03 | Process for the production of amorphous atorvastatin calcium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN775DE1999 IN191236B (pl) | 1999-05-25 | 1999-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN191236B true IN191236B (pl) | 2003-10-11 |
Family
ID=11091180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN775DE1999 IN191236B (pl) | 1999-05-25 | 1999-05-25 |
Country Status (15)
Country | Link |
---|---|
US (2) | US6528660B1 (pl) |
EP (1) | EP1185264B1 (pl) |
CN (2) | CN1680315A (pl) |
AT (1) | ATE362759T1 (pl) |
AU (1) | AU778962B2 (pl) |
BR (1) | BR0010923A (pl) |
DE (1) | DE60034946T2 (pl) |
DK (1) | DK1185264T3 (pl) |
ES (1) | ES2284472T3 (pl) |
HK (1) | HK1045118A1 (pl) |
IN (1) | IN191236B (pl) |
MY (1) | MY133511A (pl) |
PT (1) | PT1185264E (pl) |
WO (1) | WO2000071116A1 (pl) |
ZA (1) | ZA200109656B (pl) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
IN190564B (pl) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
EA005317B1 (ru) | 2001-06-29 | 2004-12-30 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Кристаллические формы [r-(r*,r*)]-2-(4-фторфенил)-бета, дельта-дигидрокси-5-(1-метилэтил)-3-фенил-4-[(фениламино)карбонил]-1h-пиррол-1-гептановой кислоты кальциевой соли (2:1) (аторвастатин) |
CA2456095C (en) * | 2001-08-31 | 2010-05-11 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
AU2004228607B2 (en) | 2003-04-11 | 2011-01-27 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
ATE406946T1 (de) * | 2003-04-29 | 2008-09-15 | Organon Nv | Verfahren zur verfestigung, bei welchem ein anti- lösungsmittel benutzt wird |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
EP1727795B1 (en) | 2004-03-17 | 2012-02-15 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
US7241800B2 (en) * | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
JP2007532622A (ja) * | 2004-04-16 | 2007-11-15 | ファイザー・プロダクツ・インク | 非晶質アトルバスタチン・カルシウムの形成方法 |
EP2540704B1 (en) | 2004-05-05 | 2019-07-03 | Pfizer Products Inc. | Benethamine salt forms of atorvastatin |
CA2573969C (en) * | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
CA2573771C (en) | 2004-07-20 | 2011-05-10 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
EP1784389A4 (en) | 2004-08-27 | 2009-03-25 | Biocon Ltd | PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM |
EP1716114A1 (en) * | 2004-10-18 | 2006-11-02 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
AU2005298383A1 (en) * | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
WO2006048888A1 (en) * | 2004-11-01 | 2006-05-11 | Jubilant Organosys Limited | Novel process for the preparation of amorphous atorvastatin calcium salt |
US20090208539A1 (en) | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
WO2007052296A2 (en) * | 2005-08-23 | 2007-05-10 | Kopran Research Laboratories Ltd | A process of preparing amorphous atorvastatin calcium |
US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
WO2008053312A2 (en) * | 2006-11-02 | 2008-05-08 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate |
US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
AU2008281640A1 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
CN101684090B (zh) * | 2008-09-27 | 2012-12-05 | 广东东阳光药业有限公司 | 一种制备无定形阿托伐他汀钙的方法 |
US8115015B2 (en) | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
WO2016055934A1 (en) * | 2014-10-09 | 2016-04-14 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU44680B (en) * | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
EP1148049B1 (en) * | 1995-07-17 | 2004-12-15 | Warner-Lambert Company | Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
-
1999
- 1999-05-25 IN IN775DE1999 patent/IN191236B/en unknown
-
2000
- 2000-01-06 DE DE60034946T patent/DE60034946T2/de not_active Expired - Lifetime
- 2000-01-06 US US09/979,475 patent/US6528660B1/en not_active Expired - Lifetime
- 2000-01-06 BR BR0010923-1A patent/BR0010923A/pt not_active IP Right Cessation
- 2000-01-06 PT PT00900300T patent/PT1185264E/pt unknown
- 2000-01-06 AU AU19967/00A patent/AU778962B2/en not_active Ceased
- 2000-01-06 CN CNA2005100525833A patent/CN1680315A/zh active Pending
- 2000-01-06 DK DK00900300T patent/DK1185264T3/da active
- 2000-01-06 CN CNB008080275A patent/CN1196679C/zh not_active Expired - Fee Related
- 2000-01-06 WO PCT/IB2000/000014 patent/WO2000071116A1/en active IP Right Grant
- 2000-01-06 AT AT00900300T patent/ATE362759T1/de active
- 2000-01-06 ES ES00900300T patent/ES2284472T3/es not_active Expired - Lifetime
- 2000-01-06 EP EP00900300A patent/EP1185264B1/en not_active Expired - Lifetime
- 2000-05-24 MY MYPI20002283A patent/MY133511A/en unknown
-
2001
- 2001-11-23 ZA ZA200109656A patent/ZA200109656B/en unknown
-
2002
- 2002-09-12 HK HK02106699.9A patent/HK1045118A1/zh unknown
-
2003
- 2003-03-03 US US10/378,574 patent/US20030149279A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0010923A (pt) | 2002-07-16 |
US6528660B1 (en) | 2003-03-04 |
AU1996700A (en) | 2000-12-12 |
WO2000071116A1 (en) | 2000-11-30 |
MY133511A (en) | 2007-11-30 |
ATE362759T1 (de) | 2007-06-15 |
AU778962B2 (en) | 2004-12-23 |
PT1185264E (pt) | 2007-07-10 |
US20030149279A1 (en) | 2003-08-07 |
DK1185264T3 (da) | 2007-08-20 |
HK1045118A1 (zh) | 2002-11-15 |
CN1680315A (zh) | 2005-10-12 |
DE60034946T2 (de) | 2008-01-17 |
ES2284472T3 (es) | 2007-11-16 |
DE60034946D1 (de) | 2007-07-05 |
EP1185264B1 (en) | 2007-05-23 |
CN1196679C (zh) | 2005-04-13 |
CN1351493A (zh) | 2002-05-29 |
ZA200109656B (en) | 2002-06-27 |
EP1185264A1 (en) | 2002-03-13 |